Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Frevecitinib - Kinaset Therapeutics/Vectura

Next Previous
Drug Profile

Frevecitinib - Kinaset Therapeutics/Vectura

Alternative Names: KN-002 - Kinaset Therapeutics/Vectura; VR-588

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vectura
  • Developer Imperial College of Science, Technology and Medicine; Kinaset Therapeutics; Vectura
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors; TRPV1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease
  • No development reported Inflammation

Most Recent Events

  • 29 Jan 2025 The US FDA approves IND application for frevecitinib in Asthma
  • 07 Sep 2024 Adverse event and pharmacokinetics data from phase I trial in Asthma and Chronic-obstructive-pulmonary-disease presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
  • 04 Sep 2024 phase-I development in Asthma and Chronic-obstructive-pulmonary-disease is ongoing in United Kingdom (Inhalation, Powder) (NCT05006521)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top